TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3675514

Group type: EXPERIMENTAL
Intervention: Controlled exercise (five deep knee bends followed by five upward arm extensions with 5‐lb weights every 15 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-exercise condition (sedentary)
Number of subjects: 0
Study: 28452112

Group type: EXPERIMENTAL
Intervention: 6-week exercise intervention (n = 50)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Wait list control (n = 49)
Number of subjects: 99
Study: 28763548

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (0.6-0.8 mg/kg/d; maximum 48 mg/d) for 2 months, followed by weaning over 4 to 6 months.
Number of subjects: 262

Group type: COMPARATOR
Intervention: Matching placebo for 2 months, followed by weaning over 4 to 6 months.
Number of subjects: 262
Study: 25618178

Group type: EXPERIMENTAL
Intervention: Ovarian drilling with bipolar energy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ovarian hyperstimulation with FSH + insemination + metformin
Number of subjects: 126
Study: 22940159

Group type: EXPERIMENTAL
Intervention: Directive visual-motor intervention (DVMI)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Non-directive supportive intervention (NDSI)
Number of subjects: 116
Study: 20564075

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil, doxorubicin, and cyclophosphamide with or without paclitaxel
Number of subjects: 42
Study: 18219451

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) applied to bilateral Hegu (LI4) and Neiguan (PC6) points, starting 30 min before analgesia induction to 24 h after operation.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham TEAS (Control)
Number of subjects: 60
Study: 16825492

Group type: EXPERIMENTAL
Intervention: Platelets stored in plasma
Number of subjects: 168

Group type: COMPARATOR
Intervention: Platelets stored in PAS II
Number of subjects: 168
Study: 14659529

Group type: EXPERIMENTAL
Intervention: Baseline psychological measures during drug-free period
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Baseline catastrophizing
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Increasing activity in response to pain
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ignoring pain sensations at baseline
Number of subjects: 68
Study: 10759689

Group type: EXPERIMENTAL
Intervention: Reviparin (s.c. injection of 6300 anti-Xa units)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA 300 mg o.d. from day 1-5)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of reviparin and ASA
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA 300 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Reviparin with ASA
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined treatment with ASA and reviparin
Number of subjects: 9
Study: 8623941

Group type: EXPERIMENTAL
Intervention: Common facts presented via headphones (Group A, 29 patients)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Familiar or unfamiliar full names of fictitious people (Group B, 29 patients)
Number of subjects: 58
Study: 1460166

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 216
Study: 30635887

Group type: EXPERIMENTAL
Intervention: Daily single-dose triple therapy (esomeprazole 40 mg, tinidazole 1 g, levofloxacin 500 mg once-daily for 14 days)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Conventional triple therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg twice-daily for 14 days)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Daily single-dose triple therapy
Number of subjects: 212

Group type: COMPARATOR
Intervention: Conventional triple therapy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 212
Study: 27233377

Group type: EXPERIMENTAL
Intervention: Continuous alternating therapy (CAT) with inhaled aztreonam (AZLI) and tobramycin inhalation solution (TIS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo/TIS
Number of subjects: 90
Study: 24677394

Group type: EXPERIMENTAL
Intervention: Decision Navigation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study: 22704737

Group type: EXPERIMENTAL
Intervention: Luminex immunoassay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Membrane-based ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mosaic ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytometric bead assays (CBA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ELISA (gold standard)
Number of subjects: 0
Study: 19968808

Group type: EXPERIMENTAL
Intervention: Remifentanil bolus dose (3.1 mcg x kg(‐1) for group I, 3.7 mcg x kg(‐1) for group II, 3.0 mcg x kg(‐1) for group III)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Remifentanil bolus dose (3.1-3.7 mcg x kg(‐1))
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Remifentanil ED(50)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Remifentanil ED(95)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Age comparison
Number of subjects: 64
Study: 19007075

Group type: EXPERIMENTAL
Intervention: Gelatamp colloidal silver gelatin sponge
Number of subjects: 672

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 672
Study: 16280829

Group type: EXPERIMENTAL
Intervention: Firm polymer stent (Percuflex, group 1)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Soft polymer stent (Contour, group 2)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study: 14642512

Group type: EXPERIMENTAL
Intervention: Deltoid to triceps transfer
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Biceps to triceps transfer
Number of subjects: 9
Study: 10784479

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8970221

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 24
Study: 1614047

Group type: EXPERIMENTAL
Intervention: 1.36% glucose solution
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 2.27% glucose solution
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 3.86% glucose solution
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All glucose solutions (1.36%, 2.27%, 3.86%)
Number of subjects: 33
Study: 6392282

Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: metronidazole
Number of subjects: 100
Study: 30654298

Group type: EXPERIMENTAL
Intervention: nal-IRI + 5-FU/LV
Number of subjects: 382

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 382
Study: 29112514

Group type: EXPERIMENTAL
Intervention: Intravenous cold saline (CS) (4°C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous room temperature saline (RS) (22°C)
Number of subjects: 12
Study: 27567528

Group type: EXPERIMENTAL
Intervention: 21-point awareness scale
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other scale lengths (not specified)
Number of subjects: 0
Study: 24265104

Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg) administered 1 hr before therapy sessions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo administered 1 hr before therapy sessions
Number of subjects: 22
Study: 22210231

Group type: EXPERIMENTAL
Intervention: TIVA group (propofol-remifentanil-N2O)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Inhalation group (sevoflurane-N2O)
Number of subjects: 46
Study: 20563735

Group type: EXPERIMENTAL
Intervention: Topical tramadol (2 mg/kg diluted in 10 ml saline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (10 ml saline)
Number of subjects: 40
Study: 17049322

Group type: COMPARATOR
Intervention: Propofol plus placebo (group A)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Propofol plus midazolam (group B)
Number of subjects: 270
Study: 11339443

Group type: EXPERIMENTAL
Intervention: Folic acid (0.5-5 mg daily)
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Vitamin B12 (mean 0.5 mg daily)
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (mean 16.5 mg daily)
Number of subjects: 1114
Study: 9347206

Group type: EXPERIMENTAL
Intervention: Oral triphasic contraceptive steroids (ethinyl estradiol and levonorgestrel)
Number of subjects: 112
Study: 8137343

Group type: EXPERIMENTAL
Intervention: Chronic low dose etoposide administration (21 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequent weekly or twice weekly administration of larger intravenous doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of active intracellular drug concentrations
Number of subjects: 0
Study: 3533811

Group type: EXPERIMENTAL
Intervention: 10 micrograms L‐triiodothyronine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30572991

Group type: EXPERIMENTAL
Intervention: Vitamin A (1,500-2,000 IU daily)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Non-intervention (Insulin treatment only)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (25 healthy children)
Number of subjects: 46
Study: 26954945

Group type: EXPERIMENTAL
Intervention: Fractionated coconut oil 1.0 mL infused in the uterus on Day 10 (Group 1; n = 5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fractionated coconut oil 0.5 mL infused in the uterus on Day 10 (Group 2; n = 5)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n = 5)
Number of subjects: 18
Study: 24997853

Group type: COMPARATOR
Intervention: 20mg E4 per day for 14 days
Number of subjects: 30
Study: 23252201

Group type: EXPERIMENTAL
Intervention: 1 g of cefoxitin
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.1 ml of vitamin B complex intravenously
Number of subjects: 84
Study: 19927027

Group type: EXPERIMENTAL
Intervention: 35% protein (approximately 2.3 g x kg(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: 15% protein (approximately 1.0 g x kg(‐1))
Number of subjects: 20
Study: 18700714

Group type: EXPERIMENTAL
Intervention: Abhay M vaccine
Number of subjects: 600

Group type: COMPARATOR
Intervention: M-Vac vaccine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 600
Study: 15616965

Group type: EXPERIMENTAL
Intervention: Transcranial (tc) stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lumbosacral (ls) stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ratio of tx/ls latencies
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tc evoked mechanical pressure responses
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EPC and MEP diagnostic tool
Number of subjects: 42
Study: 12879826

Group type: EXPERIMENTAL
Intervention: Nutrition training programme delivered by a dietitian to primary care teams.
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (no nutrition training programme).
Number of subjects: 251
Study: 10392981

Group type: EXPERIMENTAL
Intervention: 81 mg acetylsalicylic acid daily
Number of subjects: 2849

Group type: EXPERIMENTAL
Intervention: 325 mg acetylsalicylic acid daily
Number of subjects: 2849

Group type: COMPARATOR
Intervention: 650 mg acetylsalicylic acid daily
Number of subjects: 2849

Group type: COMPARATOR
Intervention: 1300 mg acetylsalicylic acid daily
Number of subjects: 2849

Group type: EXPERIMENTAL
Intervention: Efficacy analysis excluding patients taking 650 mg or more acetylsalicylic acid
Number of subjects: 2849
Study: 8844276

Group type: EXPERIMENTAL
Intervention: MACTres (increased resistance, constant frequency at 100 rpm)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MACTfreq (increased frequency, constant resistance at 0.077 x body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: MART (maximal anaerobic running test)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MACTres
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MACTfreq
Number of subjects: 10

Group type: COMPARATOR
Intervention: MART
Number of subjects: 10
Study: 2066454

Group type: EXPERIMENTAL
Intervention: Adinazolam (60-90 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Amitriptyline (150-225 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Diazepam (30-45 mg/day)
Number of subjects: 66
Study: 31116170

Group type: EXPERIMENTAL
Intervention: Nonphysician competent facilitators (NPCFs)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Attending physician faculty
Number of subjects: 85
Study: 28122361

Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: Non-antiviral therapy
Number of subjects: 174
Study: 26406981

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing cinnamon, chromium and carnosine (1.2 g/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 23579179

Group type: EXPERIMENTAL
Intervention: TeenCope
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Managing Diabetes
Number of subjects: 320
Study: 21269484

Group type: EXPERIMENTAL
Intervention: EPO therapy (5,000 IU subcutaneously at 48 h and 72 h after acute IS)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: EPO therapy (group 1)
Number of subjects: 167
Study: 19705951

Group type: EXPERIMENTAL
Intervention: Mandibular cervical headgear (MCH) and fixed appliances
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated Class III subjects)
Number of subjects: 20
Study: 17989311

Group type: EXPERIMENTAL
Intervention: Provider surveys
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Patient focus groups
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Medical chart audits
Number of subjects: 303
Study: 15944887

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program (five sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention placebo control condition
Number of subjects: 40
Study: 11845860

Group type: EXPERIMENTAL
Intervention: Ministernotomy (group I, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional sternotomy (group II, n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ministernotomy (group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional sternotomy (group II)
Number of subjects: 80
Study: 10395851

Group type: EXPERIMENTAL
Intervention: Atovaquone 750 mg once a day
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Atovaquone 1500 mg once a day
Number of subjects: 549

Group type: COMPARATOR
Intervention: Aerosolized pentamidine 300 mg once a month
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Atovaquone (both dosages)
Number of subjects: 549
Study: 8847035

Group type: EXPERIMENTAL
Intervention: Octreotide 100 mcg bolus intravenously followed by 25 mcg/h intravenously for 1.4 +/- 0.6 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ranitidine 100 mg intravenously every 12 h
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 84
Study: 2289639

Group type: EXPERIMENTAL
Intervention: Diabetes protocol with self-monitoring of blood glucose (n=56)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Conventional care (control group, n=73)
Number of subjects: 129
Study: 6896575

Group type: EXPERIMENTAL
Intervention: Isaxonine (4 capsules of 375 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (4 capsules filled with lactose)
Number of subjects: 15
Study: 31445582

Group type: EXPERIMENTAL
Intervention: Intradialytic protein supplementation with exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intradialytic protein supplementation without exercise
Number of subjects: 0
Study: 27606613

Group type: EXPERIMENTAL
Intervention: 1500 ml of oral rehydration solution (rehydration group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 46
Study: 25963302

Group type: EXPERIMENTAL
Intervention: 10 mg pemirolast
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: 25 mg pemirolast
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: 40 mg pemirolast
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 23369651

Group type: EXPERIMENTAL
Intervention: Algorithmic approach in phase II using 25-gauge needle for transduodenal FNAs and 22-gauge needle for other FNAs; 19-gauge needle for transduodenal interventions and standard 19-gauge needle for others.
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Algorithmic approach in phase II.
Number of subjects: 1048
Study: 21374079

Group type: EXPERIMENTAL
Intervention: Visual and haptic cues presented with temporal disparity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual and haptic cues presented synchronously
Number of subjects: 0
Study: 19692922

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C 1.5 times upper intake level, vitamin E 1.35 times upper intake level, zinc 2.0 times recommended dietary allowance) for 7 days starting on the second day of hospital admission
Number of subjects: 32

Group type: COMPARATOR
Intervention: No supplementation (placebo)
Number of subjects: 32
Study: 17984344

Group type: EXPERIMENTAL
Intervention: Human and bovine praziquantel treatment
Number of subjects: 5390

Group type: COMPARATOR
Intervention: Human praziquantel treatment only
Number of subjects: 5390

Group type: EXPERIMENTAL
Intervention: Bovine contamination index calculations
Number of subjects: 5390
Study: 15119493

Group type: EXPERIMENTAL
Intervention: Benzodiazepine treatment program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Observation with CIWA-Ar administered every eight hours for 48 hours
Number of subjects: 16
Study: 11913311

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-containing chewing gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium bicarbonate-containing toothpaste
Number of subjects: 0
Study: 9152681

Group type: COMPARATOR
Intervention: diet AP (western animal protein-rich diet)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: diet VP (soy protein-rich vegetable diet)
Number of subjects: 12
Study: 8178407

Group type: EXPERIMENTAL
Intervention: BCG Connaught 120 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Interferon A 10(7) units
Number of subjects: 78
Study: 2906556

Group type: EXPERIMENTAL
Intervention: L-tyrosine 50, 250 and 500 mg kg-1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: L-tyrosine 250 and 500 mg kg-1 with idazoxan (0.1 mg kg-1 i.v.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Idazoxan (0.1 mg kg-1 i.v.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31023832

Group type: EXPERIMENTAL
Intervention: Postoperative plasma vitamin D (25OHD) level
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Postoperative plasma C-reactive protein (CRP) level
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Preoperative vs postoperative plasma 25OHD levels
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Postoperative plasma 25OHD recovery
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 25OHD tertile and CRC mortality
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 25OHD tertile and all-cause mortality
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Plasma 25OHD and rs11568820 genotype interaction
Number of subjects: 92
Study: 29921320

Group type: EXPERIMENTAL
Intervention: Navoximod (GDC-0919) administered at doses of 50-800 mg BID on a 21/28 day schedule and 600 mg on a 28/28 day schedule
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Navoximod (GDC-0919)
Number of subjects: 22
Study: 27418458

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No EMD (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (EMD and control)
Number of subjects: 26
Study: 25284751

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 500 mg, six capsules twice daily for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24321164

Group type: EXPERIMENTAL
Intervention: Amantadine 200mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALCAR) 2g
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20464812

Group type: EXPERIMENTAL
Intervention: Exercise in 25 degrees C water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise in 38.5 degrees C water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Change in core temperature (T(re)) during exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Change in cortisol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Change in TNF-alpha
Number of subjects: 8
Study: 18538054

Group type: EXPERIMENTAL
Intervention: 60 mL 0.25% levobupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 60 mL saline placebo (control group)
Number of subjects: 50
Study: 15855886

Group type: EXPERIMENTAL
Intervention: Somatosensory and motor evoked potentials (SEP and MEP) examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation for measuring central and peripheral conduction time (CCT and PCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of volunteers
Number of subjects: 0
Study: 11823754

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml)
Number of subjects: 24
Study: 10508948

Group type: EXPERIMENTAL
Intervention: Subaxillary extrapleural approach
Number of subjects: 836

Group type: COMPARATOR
Intervention: Routine surgical technique (posterolateral approach)
Number of subjects: 836
Study: 7717487

Group type: EXPERIMENTAL
Intervention: Thiopentone (step 1: 1.25 mg.kg‐1 followed by 2.5 mg.kg‐1.h‐1; step 2: 1.25 mg.kg‐1 and 12.5 mg.kg‐1.h‐1; n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol (step 1: 0.5 mg.kg‐1, 1 mg.kg‐1.h‐1; step 2: 0.5 mg.kg‐1, 5 mg.kg‐1.h‐1; n = 15)
Number of subjects: 30
Study: 1645643

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 838
Study: 6791864

Group type: EXPERIMENTAL
Intervention: Penicillin (55 mg/kg/day for 7 days)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 149

Group type: COMPARATOR
Intervention: Penicillin and Placebo
Number of subjects: 149